

European Contract Biomanufacturing Organizations – CbMO Market Outlook

Date: 9/3/2011

By Philippe Tramoy, Claude Bensoussan

Copyright 2011 CBDM.T SARL. All rights reserved. Any unauthorized use or disclosure is prohibited. The information herein was obtained from various sources; we do not guarantee its accuracy or completeness. This research report is prepared for general circulation and is circulated for general information only. It does not have regard to specific investment objectives, financial situations and the particular needs of any particular person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities or investment and trading strategies discussed or recommended in this report and should understand that the statements regarding future prospects may not be realized. Investors should note that income from such securities, if any, may fluctuate and that each security's price or value may rise or fall. Accordingly, investors may receive back less than originally invested. Past performance is not necessarily a guide to future performance. Neither the information nor any opinion expressed constitutes an offer to buy or sell any securities or options or futures contracts. CBDM.T SARL accepts no responsibility or liability whatsoever for any expense, loss or damages arising out of or in any way connected with the use of all or any part of this report. CBDM.T SARL does not have long or short position in any securities or options of this issue(s).



Philippe Tramoy

Philippe Tramoy is a market and business intelligence expert. He has previously conducted Research and Business Development projects. He holds a Masters in Finance, a Masters in Intelligence Marketing, an MSc in Biochemistry and an MSc in Genetics & Immunology. In 2000, he joined Rhodia Chirex as Europe Business Development Manager for biotechnology and biopharmaceutical companies.

In 2004, he founded CBDMT – Market & Business Intelligence. CBDM.T® is a market and business intelligence company with offices in France, Switzerland and Israel. As an advisory services company, CBDM.T® boosts companies to develop revenue and growth by providing business and marketing services in the life science and biotech markets (market surveys, market scouting, business development and strategic supports).

<http://fr.linkedin.com/in/philippetramoy>
www.cbdmt.com

Claude Bensoussan

Claude Bensoussan is a bioproduction expert. He has previously conducted R&D and industrial projects in the bioproduction field. He has a PhD degree in Molecular Pharmacology. In 1987, he joined Rhône-Poulenc Santé's Vitry Research Centre as a toxicology researcher. He subsequently specialized in biotechnology and was appointed (in 1996) Director of the Biotransformation Group at Rhône-Poulenc Rorer. In 2000, he joined Rhodia as Director of the Biocatalysis Department and Biotech Project Director at the company's Research Centre in Lyon.

In 2005, he created BioAdvice®, an operational consultancy firm in the field of bioprocess and bioproduct development. BioAdvice and CBDM.T have collaborated since early 2006 in the mapping of innovative technologies from the biotechnology areas and in advisory services.

<http://fr.linkedin.com/in/claudebensoussan>
www.bioadviceonline.com

Copyright©2011 CBDM.T SARL – This Report is published by CBDM.T Market and Business Intelligence SARL. Reproduction or redistribution of this report in any form for any purpose is expressly prohibited without the prior consent of CBDM.T SARL. CBDM.T accepts no liability for the accuracy or completeness of the information, advice or comment contained in this report, nor for any actions taken in reliance thereon. While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by CBDM.T for its completeness or accuracy.



Table of Contents

Executive Summary	13
Chapter I – General Information	15
Introduction.....	16
The European context	17
Objectives.....	18
Methodology.....	19
History of contract manufacturing organizations	19
Lonza.....	19
DSM Biologics	19
Angel biotechnology.....	20
Lactosan.....	20
Safisis	20
National Biomanufacturing Center	21
Market served and product types	22
The biopharmaceutical segment.....	22
Monoclonal antibodies.....	23
Vaccines.....	25
Recombinant proteins	25
The industrial biotechnology segment.....	26
Technical enzymes.....	27
Environment	29
Biofuels.....	30
The food segment.....	31
The feed segment.....	33
The cosmetics segment	34
The agricultural segment.....	36
Biomanufacturing technologies and processes.....	39
The different production systems	39
Microbial fermentation	39
Biocatalysis	40
Mammalian cell culture.....	42

Transgenic animals	43
Transgenic plants.....	44
The upstream process development (UPS)	47
Cell line development.....	48
Process development	48
Harvest and concentration.....	50
The downstream process development (DSP)	51
Purification	51
Fill & Finish	52
Outsourcing Biomanufacturing	53
Make versus buy decision	53
Key selection criteria	55
Chapter II –European Contract BioManufacturing Organizations	57
Statistical population.....	58
Situation	59
Number of companies.....	59
Location	60
Quality assurance and certifications	64
Expression platforms.....	66
Segmentation	67
Size and Capacity.....	71
Scale.....	71
Production capacity.....	72
Total European production capacity	72
Mammalian cell culture capacity	72
Microbial fermentation capacity.....	76
Additional services	78
Forecast	80
The rise of biopharmaceuticals and industrial biotechnology	80
Biopharmaceuticals lead the contract manufacturing market	80
Increased interest for bio-based processes and materials	81
Increasing competition and intellectual property concerns	83
From larger bioreactors to additional services	83

Emergence of alternative expression systems.....	85
Chapter III – The Contract Biomanufacturing Market.....	87
Global Contract Biomanufacturing Market.....	88
The Biopharmaceutical Market.....	91
Market situation and evolution.....	92
Monoclonal antibodies.....	94
Vaccines.....	97
Recombinant proteins.....	97
Contract BioManufacturing companies and offer.....	101
The Food Market.....	109
Market situation and evolution.....	110
Food additives.....	111
Food supplements.....	111
Probiotics.....	113
Processing aids.....	113
Contract biomanufacturing companies and offer.....	115
The Industrial Biotechnology Market.....	121
Market situation and evolution.....	122
Technical enzymes.....	122
Environmental applications.....	124
Bioremediation.....	124
Biopolymers.....	125
Contract biomanufacturing companies and offer.....	127
The Feed Market.....	131
Market situation and evolution.....	132
Feed additives.....	133
Feed enzymes.....	134
Contract biomanufacturing companies and offer.....	135
The Cosmetics Market.....	140
Market situation and evolution.....	141
Contract biomanufacturing companies and offer.....	143
The Bio-Agricultural Market.....	147
Market situation and evolution.....	148



Biopesticides.....	148
Biofertilizers.....	149
Contract biomanufacturing companies and offer.....	150
Chapter IV - Key Players	154
Lonza	155
Boehringer Ingelheim.....	159
DSM Biologics.....	162
Diosynth Biotechnology	165
Roche.....	168
Sandoz	171
BioVet.....	174
Danisco.....	176
Cambrex	180
SAFC Biosciences.....	183
Lallemand.....	186

List of Tables

Table 1 Examples of Biomanufacturing Applications.....	17
Table 2 Biopharmaceutical Products.....	22
Table 3 List of Therapeutic Monoclonal Antibodies Approved.....	23
Table 4 Some Commercial Enzymes and Source Microorganisms.....	27
Table 5 Some Detergent Enzymes and Their Action.....	28
Table 6 Application of Hydrolase Enzyme in Fabric Preparation.....	28
Table 7 Application of Oxidoreductase in Fabric Preparation.....	29
Table 8 The Different Types of Food Ingredients.....	31
Table 9 Feed Ingredients Manufacturing Deals with European CMOs.....	34
Table 10 Selected Ingredients Segments and Leading Products.....	35
Table 11 Biopesticide Products and Companies.....	37
Table 12 Microbial Expression Systems.....	40
Table 13 Methods Used to Develop Chiral Compounds.....	41
Table 14 Biocatalysis in Industry-Examples.....	42
Table 15 Therapeutic Proteins Produced in the Milk of Transgenic Animals that are Currently in Commercial Development.....	43
Table 16 Comparison of Expression Systems.....	45
Table 17 Cleanroom Standards.....	52
Table 18 Capital Investment Costs for Biopharmaceutical Facilities in Europe.....	53
Table 19 CMOs' Key Data.....	58
Table 20 Example of Companies Running Multiple Factories.....	60
Table 21 CMOs' Average Number of Employees.....	63
Table 22 Examples of Regulatory Agencies.....	64
Table 23 Comparison of Mammalian Cell Culture Capabilities Between France and the Netherlands (average data).....	75
Table 24 Estimated Requirements for Top Selling Biopharmaceuticals.....	85
Table 25 New Biologic License Application (BLA) Approvals, 2009.....	94
Table 26 Therapeutic Antibodies Manufacturing Deals with European CMOs.....	96
Table 27 Vaccine Manufacturing Deals with European CMOs.....	97
Table 28 Recombinant Protein Manufacturing Deals with European CMOs.....	99
Table 29 CMOs' Key Data for the Biopharmaceutical Market.....	101
Table 30 Biopharmaceutical Key CMOs Using Microbial Fermentation.....	104
Table 31 Biopharmaceutical Key CMOs Using Mammalian Cell Culture.....	106
Table 32 CMOs' Key data for the Food Market.....	115
Table 33 Comparison of R&D Expenditures Between a Pharmaceutical and a Food Company, 2009.....	116
Table 34 Food Ingredients Key CMOs.....	116
Table 35 CMOs' Key Data for the Industrial Biotechnology Market.....	127
Table 36 Industrial Biotechnology Key CMOs.....	128
Table 37 CMOs' Key Data for the Feed Market.....	135
Table 38 Feed Additives Key CMOs.....	136
Table 39 CMOs Key Data for the Cosmetic Market.....	143



Table 40 Cosmetic Ingredients Key CMOs.....	144
Table 41 CMOs' Key Data for the Bio-Agricultural Market	150
Table 42 Agricultural Bioproducts Key CMOs	150

List of Figures

Figure 1 Industrial Biotechnology Application	26
Figure 2 Biopolymers Products, Applications and Companies	30
Figure 3 Probiotic Supplement Align™ Based on Bifidobacterium infantis	33
Figure 4 Fungicide Serenade® Based on Bacillus subtilis	38
Figure 5 The Chiral Technologies Market, 2002 – 2009	41
Figure 6 Upstream Manufacturing Process Overview.....	47
Figure 7 Depth Filtration Pore Design	50
Figure 8 Downstream Manufacturing Process Overview Example	51
Figure 9 Recombinant Therapeutic Protein's Probability of Successful Development.....	55
Figure 10 Critical Factors When Outsourcing Biomanufacturing.....	56
Figure 11 History of CMOs' Establishment.....	59
Figure 12 European CMOs' Facilities Localization by Country	61
Figure 13 European CMOs Mapping	62
Figure 14 Nationality of CMOs established in Europe	62
Figure 15 Contract Biomanufacturing Facilities Certifications.....	64
Figure 16 Biosafety Accredited European Biomanufacturing Facilities	65
Figure 17 Expression Systems Utilization Ratios, all CMOs considered	66
Figure 18 Expression Systems Utilization Ratios, Multi-P versus AB-only CMOs.....	67
Figure 19 Number of Production Sites By Contract BioManufacturing Market Segment and By Type of CMOs.....	67
Figure 20 Contract Biomanufacturing Served Market, by Expression System Type (Total 143 Microbial sites + 60 Mammalian sites).....	68
Figure 21 Products Manufactured Using Mammalian Cell Culture.....	69
Figure 22 number of production microbial fermentation site by type of product (Total 143 sites)	70
Figure 23 CMOs' Production Scales.....	71
Figure 24 European CMOs' Total Available Production Capacity.....	72
Figure 25 CMO's Mammalian Production Capacity.....	73
Figure 26 Mammalian Production Capacities, Sites and Companies by Country (Top 5).....	73
Figure 27 Mammalian Production Capacities, Sites and Companies, by Country (Last 12).....	74
Figure 28 Comparison of Contract Biomanufacturing Capability Between France and the Netherlands	75
Figure 29 CMO's Microbial Production Capacity.....	76
Figure 30 Microbial Production Capacities, Sites and Companies by Country (Top 10)	77
Figure 31 Microbial Production Capacities, Sites and Companies by Country (Last 15).....	77
Figure 32 CMOs' Additional Services.....	78
Figure 33 CMOs' Fill & Finish Services	79
Figure 34 Number of Approved Biotech Drugs and Global Biotech Revenues, 1990 – 2005	80
Figure 35 The Triple-P Bottom Line.....	82
Figure 36 Fermentation Volume Required Depending on Yield and Market Demand	84
Figure 37 European Contract Biomanufacturing Organizations Business Positioning and Potential Market Sizes	88

Figure 38 The Contract Biomanufacturing Market, 2005 – 2015.....	89
Figure 39 The Contract Biomanufacturing Market, 2007	89
Figure 40 The European Biotechnology Market in 2008.....	92
Figure 41 The Biopharmaceutical Market, 2005 – 2009	93
Figure 42 Sales of Monoclonal Antibodies Produced by CMOs Versus In-house	95
Figure 43 Recombinant Proteins Market Size Growth to 2010.....	98
Figure 44 Sales Forecasts for Top20 Recombinant Proteins, by Product Class.....	98
Figure 45 Nationality of CMOs Established in Europe, Supplying the Biopharmaceutical Market.....	101
Figure 46 Expression Systems Used for Biopharmaceutical Production.....	102
Figure 47 Biopharmaceutical Outsourcing Evolution, 2003-2006	103
Figure 48 European CMOs' Biopharmaceuticals Production Sites and Capacities Using Microbial Fermentation, by Country	104
Figure 49 European CMOs' Biopharmaceutical Production Sites and Capacities Using Mammalian Cell Culture, by Country	105
Figure 50 Number of GMP and non-GMP Production Sites, by Product Class	106
Figure 51 CMOs' Capacity of Supplying Clinical Lots.....	107
Figure 52 Global Food Bio-Ingredients Market, 2007	110
Figure 53 The Food Additives Market	111
Figure 54 Global Food Supplement Market, 2006	112
Figure 55 The Probiotics Market, 2007-2013.....	113
Figure 56 The Food Processing Enzymes Market, 2004-2008.....	114
Figure 57 Nationality of CMOs Established in Europe, Supplying the Food Market.....	115
Figure 58 European CMOs' Food Ingredients Production Sites and Capacities, by Country	117
Figure 59 Number of Production Sites Supplying the Food Market, by Type of Expression System and Scale.....	118
Figure 60 CMOs Certifications for the Food Market	119
Figure 61 The Industrial Biotechnology Market, 2010.....	122
Figure 62 The Global Industrial Enzymes Market, 2002 – 2012.....	123
Figure 63 The Global Technical Enzymes Market, 2002 – 2012.....	123
Figure 64 The U.S Environmental Biotechnology for Waste Treatment Market, 2006 – 2012	124
Figure 65 Annual Bioplastics Production Capacity, 2007 – 2011	125
Figure 66 The Global Biopolymer Market, 2007 – 2012	126
Figure 67 Nationality of CMOs Established in Europe, Supplying the Industrial Biotechnology Market	127
Figure 68 European CMOs' Industrial Biotechnology Production Sites and Capacities, by Country ..	128
Figure 69 Number of Production Sites Supplying the Industrial Biotechnology Market, by Type of Expression System and Scale.....	129
Figure 70 CMOs Certifications for the Industrial Biotechnology Market.....	129
Figure 71 Top 10 Countries in Industrial Feed Production by Region, 2005.....	132
Figure 72 Global Feed Bio-Ingredient Market, 2010.....	133
Figure 73 The World Animal Feed Additives Market, 2010 – 2015	134
Figure 74 Nationality of CMOs Established in Europe, Supplying the Feed Ingredients Market	135
Figure 75 European CMOs' Feed Ingredients Production Sites and Capacities, by Country	136

Figure 76 Number of Production Sites Supplying the Feed Market, by Type of Expression System and Scale.....	137
Figure 77 Economies of Scale	137
Figure 78 CMOs Certifications for the Feed Market	138
Figure 79 Cosmetic ingredients market, 2008	141
Figure 80 Global Consumption of Personal Care Ingredients	142
Figure 81 Nationality of CMOs Established in Europe, Supplying the Cosmetic Ingredients Market.	143
Figure 82 European CMOs' Cosmetic Ingredients Production Sites and Capacities, by Country	144
Figure 83 Number of Production Sites Supplying the Cosmetic Market, by Type of Expression System and Scale.....	145
Figure 84 CMOs Certifications for the Cosmetic Market	145
Figure 85 The Agricultural Bioproducts Market, 2009	148
Figure 86 The Global Pesticide Market, 2003 - 2014	149
Figure 87 Nationality of CMOs Established in Europe, Supplying the Bio-Agricultural Market.....	150
Figure 88 European CMOs' Agricultural Bioproducts Production Sites and Capacities, by Country ..	151
Figure 89 Number of Production Sites Supplying the Bio-Agricultural Market, by Type of Expression System and Scale.....	151
Figure 90 CMOs Certifications for the Bio-Agricultural Market	152